Charged Alpha Stock Encyclopedia

About Charged Alpha Stock Encyclopedia

⚡ Charged Alpha — The S&P 500 Stock Encyclopedia Data-driven deep dives into every stock in the S&P 500 after every earnings report. Each episode breaks down one company from open to close: what they do, how the numbers look, what Wall Street thinks, the bull case, the bear case. 🛠️ Check out our free beginner-friendly screening tools for stocks, ETFs, options, crypto, bonds, REITs & more at https://chargedalpha.com — no signup, no paywall. 📊 What you get in every episode: Company overview & competitive moat Full financial breakdown — valuation, revenue, margins, cash flow Analyst consensus & price targets Bull case vs. bear case Peer comparison, options flow & insider activity Key metrics to watch ⚠️ Not financial advice. For educational purposes only. Episodes are researched, written, and produced using AI-assisted tools. All data aggregated from publicly available sources. #stocks #investing #S&P500 #stockanalysis #chargedalpha #financialdata #earningsreport #earnings

Publisher

Colton Thomas

Category

business

Language

en

Explicit

No

First episode

7 Apr 2026

Latest episode

29 Aug 2026

Latest episodes

1 of 960 episodes have a transcript.

1. 

   29 Aug 2026

   Materialise (MTLS): One Segment Earns 118% Of The Profit

   Materialise (MTLS) Q2 2026 — Q2 2026 (three months to 30 June, filed in EUR): revenue EUR70.1M, +8.1% YoY; adjusted EBIT EUR3.9M, +26.9%; net profit EUR3.3M, EUR0.06 per ordinary share and per ADS. But the REPORTED operating result was EUR2.8M against EUR2.7M - essentially unchanged. Full-year adjusted EBIT guidance RAISED to EUR12-14M; revenue guidance reaffirmed at EUR273-283M. The 6-K landed pre-market on 27 Aug: +11.24% on 8.2x median volume, then 53% handed back the next session to close at $7.02. One of Materialise's three businesses earned more money last half than the entire company did. Materialise Medical produced EUR20.8M of segment adjusted EBITDA in the six months to 30 June; the whole company kept EUR17.6M - 118%, on 51% of group revenue. It is not a quarter: the same ratio was 133% across 2025 and 113% across 2024. Software, the highest-quality revenue in the group, is the only segment shrinking. Manufacturing is a third of revenue and lost EUR6.2M at the segment operating line. THE CALL: HOLD (3/5, ONE SEGMENT IS THE COMPANY, AND NOTHING FORCES ANYONE TO SEPARATE IT) — base-case value ~$7.21 vs ~$7.02 today. KEY METRICS: - CALL: HOLD 3/5, fair value $7.21 vs the $7.02 close of 28 August (+2.7%). Bear $6.01 (discounted cash flow), base $7.40 (group at 8.5x guided adjusted EBITDA), bull $8.44 (sum of the parts), weighted 40/25/35. One dated Street target: Cantor Fitzgerald, Overweight, $10.00, 20 February 2026, set with the ADS at $5.48. - THE SPINE - segment adjusted EBIT, June half: Medical +EUR17.4M, Software +EUR0.8M, Manufacturing -EUR6.2M, unallocated corporate -EUR5.6M. Those four sum to the EUR6.4M of consolidated adjusted EBIT Materialise reported. - THREE YEARS, NOT ONE QUARTER: Medical was 133% of group adjusted EBITDA across 2025 and 113% across 2024. Two-year segment revenue: Medical EUR116.4M to EUR134.2M, Manufacturing EUR106.5M to EUR92.5M, Software EUR43.9M to EUR40.9M. Group revenue barely moved. - BALANCE SHEET AND CAPEX: EUR74.2M of NET CASH, a fifth of the $407.1M market value. But depreciation was EUR11.3M in the half against EUR3.4M of capital spending - 0.31x. - VENDOR ERRORS NAMED ON-SLIDE: FMP's FY2025 revenue is 3.9% BELOW the filed figure; its earnings feed carries a PHANTOM 23 July 2026 print; its market cap is 1.0% high. ONE ADS IS ONE ORDINARY SHARE, proved from note 6.2. What to watch: UP: the medical share of group adjusted EBITDA falling below 100%; two consecutive periods of software revenue GROWTH; any announced separation or disposal of a segment. DOWN: capital spending staying below depreciation; manufacturing losses widening again; the full-year revenue guide being cut in November. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

2. 

   29 Aug 2026

   JinkoSolar (JKS): The $212M Operating Loss That Was Reported As $103M

   JinkoSolar (JKS) Q2 2026 — Q2 2026 (three months to 30 June): revenue RMB12.36BN / $1,821.2M, -31.3% YoY on module shipments of 15,961MW, -34.4%; gross margin 4.2% from 8.3% in Q1; operating expenses $287.3M against $75.6M of gross profit, so a $211.7M loss from operations. Net loss attributable to ordinary shareholders $102.8M, or $1.94 per ADS - but the company's own ADJUSTED loss is $134.2M, 31% BIGGER. Full-year shipment guidance cut from 75-85GW to 60-70GW. The 6-K landed pre-market on 26 Aug: the ADSs closed -11.87% and made a fresh 12-month closing low the next session. Making and selling solar modules lost JinkoSolar $211.7M in the June quarter. The loss reported to the owners of the ADSs was $102.8M - less than half of it. Both figures are correct and both are printed on the same filed statement of operations. The $108.9M in between is five non-operating items: government grants of $29.7M, the gain on selling 75.1% of the US business ($34.9M), a fair-value mark on a portfolio of private investments ($54.6M), an income tax benefit ($24.1M), and $84.0M of the group loss carried by the MINORITY holders of the majority-owned operating subsidiary. Not one of them is a solar module, and on the same morning the company cut its full-year shipment guidance by 15GW and made its head of strategic investment the chief executive. THE CALL: SELL (3/5, A LEVERED CYCLICAL WHOSE REPORTED LOSS IS HALF THE OPERATING ONE) — base-case value ~$9.90 vs ~$13.54 today. KEY METRICS: - CALL: SELL 3/5, fair value $9.90 vs the $13.54 close of 28 August (-26.9%). Bear $4.94, base $8.89, bull $20.86, weighted 35/45/20. Below both live Street targets: Goldman Sachs cut to $11.00 and Roth Capital to $16.00, both on 27 August. Their average of $13.50 is 4 cents UNDER the last close. - THE BRIDGE: loss from operations $211.7M; net loss attributable to ordinary shareholders $102.8M; ratio 2.06x, against 1.27x in the March quarter. The five items in between total $227.3M of help against $118.4M of drags - net interest $40.3M, an exchange loss on foreign-currency debt of $48.0M, and smaller items. - THE UNIT ECONOMICS: 0.47 cents of gross profit per watt shipped against 1.80 cents of operating cost per watt - 3.8x. A quarter earlier the gross line was 1.10 cents. Gross margin must reach ~15.8% to cover the overhead; it is 4.2%, an 11.6-point gap that WIDENED from 7.7 points a year ago. - THE BALANCE SHEET: $6,617M of total interest-bearing debt less $2,497M of cash = $4,121M of net debt, 5.8x the $716M market value. Cash fell $865M in the quarter (from $3,362M at 31 March) while a $1.50/ADS dividend (~$79M) was declared. Equity attributable to JinkoSolar is $2,152M - 12.3% of $17.5BN of assets. Book value $40.72 an ADS; the tape pays 0.33x book. - TWO VENDOR ERRORS NAMED ON-SLIDE: (1) FMP's epsActual of -2.53 is the company's ADJUSTED loss per ADS, not the filed GAAP -1.94. (2) FMP's market cap of $177.3M is 75% TOO LOW - it carries 13.09M shares where the release prints 211,435,343 weighted ordinary shares, and ONE ADS REPRESENTS FOUR ORDINARY SHARES. The correction makes the stock DEARER, not cheaper. What to watch: DOWN (our case): gross profit per watt staying under 1.80 cents; a second cut to the 60-70GW guide in November; net debt holding above $4BN against a sub-$1BN equity. UP (what would change our mind): two consecutive quarters of gross profit per watt above 1.80 cents; the January 2027 efficiency standard lifting realised prices on 40GW of TOPCon 3.0 capacity; net debt falling toward the equity value. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

3. 

   29 Aug 2026

   Gaotu Techedu (GOTU): More Cash Than Market Cap - And Two Thirds Of It Is Prepaid Tuition

   Gaotu Techedu (GOTU) Q2 2026 — Q2 2026 (three months to 30 June): net revenues RMB1,670.1M / $246.1M, +20.2% YoY, accelerating from +13.2% in Q1; gross margin 66.5%; operating expenses $185.8M against $163.7M of gross profit, so a $22.1M operating loss, narrowed from $35.6M. Net loss $20.0M, RMB0.57 (-$0.09) per ADS. Operating cash inflow $126.9M, +46.3% - but the six-month figure is $4.8M, -70.6%. The 6-K landed pre-market on 27 Aug: the ADSs gapped +6.9%, faded to $1.74, closed +5.20%, and added +3.30% the next session. Gaotu holds $588.5M of cash, restricted cash and investments against a market value of $441.9M. On a screen that is a negative enterprise value. But $384.9M of that cash is deferred revenue - tuition already collected for lessons that have not been taught - and the filed shareholders' equity of $154.2M has already netted it off for you. Fund the cost of teaching every lesson already sold, at the filed 33.5% cost ratio, and $380.7M survives: $1.62 an ADS, 86% of the share price. That leaves the market paying about $61.2M for a business turning over $1.06BN at a 66.5% gross margin, still growing 20%. THE CALL: SPEC BUY (3/5, A CASH FLOOR UNDER A BUSINESS THAT STILL LOSES MONEY) — base-case value ~$2.35 vs ~$1.88 today. KEY METRICS: - CALL: SPEC BUY 3/5, fair value $2.35 vs the $1.88 close of 28 August (+25.1%). Bear $0.96, base $2.34, bull $4.04, weighted 30/45/25. Street: 10 ratings, consensus Hold, and NO live target - the newest dated note from a named firm is Citigroup's $5.81 of 5 August 2024, 754 days stale. - THE FLOOR: net cash $509.6M ($588.5M less $78.9M of borrowings) against a $441.9M market value. Deducting the whole $384.9M deferred revenue balance leaves $124.7M ($0.53 an ADS); deducting only the 33.5% cost of delivering it leaves $380.7M ($1.62 an ADS, 86% of the price). Filed shareholders' equity is $154.2M. - THE SPINE: operating cash inflow was $126.9M (+46.3%) while deferred revenue rose $120.6M over the same three months - 95% of it. The March quarter was a $122.1M OUTFLOW while deferred revenue fell $114.0M - 93% of it. Both quarters together: $4.8M against $16.4M, -70.6%. Six months of it moved the cash pile $3.0M. - THE ADS RATIO: three ADSs represent two ordinary shares. 156,703,879 ordinary shares outstanding is 235.1M ADSs, so the market value is $441.9M - not the $682.0M published, which uses 362.7M ADSs and is 54% too high. Corroborated independently by the FY2025 20-F depositary disclosure. - THE QUARTER: revenue $246.1M (+20.2%), gross margin 66.5%, operating loss $22.1M vs $35.6M. Operating costs fell to 75.5% of revenue from 83.4% - a 7.9 point move that halved the gap to operating break-even, from 17.4 points to 9.0. Selling costs alone were $134.6M, 82.2% of gross profit. - WHERE WE DISAGREE: guided Q3 revenue, this quarter's gross margin and costs grown at the +8.8% they actually grew give a FY2026 operating LOSS of $46.7M. The vendor consensus has a $5.3M operating PROFIT, on four revenue analysts and one earnings analyst. We agree on revenue to within 0.6%. Our model crosses into profit in 2028. What to watch: UP: March-quarter gross billings above last March's $146.8M; the operating cost ratio falling below 66.5% of revenue; deferred revenue continuing to grow year on year. DOWN: two consecutive quarters of deferred revenue falling year on year; refunds rising inside gross billings; the cost ratio back above 83%. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Inside a recent episode

Danaher (DHR) — Q4 2025 Earnings Deep Dive | Charged Alpha

Published 15 Apr 2026 · Transcript excerpt

[…] In life sciences, there's Beckman-Coulter Life Sciences, Sci-X for mass spectrometry, and Leica Microsystems for microscopy. And on the diagnostics side, Cepheid handles rapid molecular diagnostics, Beckman-Coulter diagnostics does the high-volume lab testing, and Radiometer covers blood gas analysis. Total revenue in 2025 came in at $24.6 billion. And here's the number I keep coming back to. Over 80% of their revenue is recurring. That's consumables, reagents, service contracts. Once a hospital or lab installs Danaher equipment, they're buying refills for years. That recurring revenue base is what gives Danaher its defensive quality. […]

Contact Charged Alpha Stock Encyclopedia

Guest appearances

Does not typically book guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.

Questions about Charged Alpha Stock Encyclopedia